查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553681

肝病治療藥物市場規模、佔有率和趨勢分析報告：按藥物類別、疾病、地區和細分市場預測，2024-2030年

Liver Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Antiviral Drugs, Vaccines), By Disease (Hepatitis, Autoimmune Diseases, Cancer), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

肝病治療藥物市場成長與趨勢：

根據 Grand View Research, Inc. Masu 的最新報告，預計到 2030 年，全球肝病治療市場將達到 286.2 億美元，2024 年至 2030 年複合年成長率為 5.7%。

主要促進因素是肝細胞癌等肝臟疾病的增加以及此類疾病患者的巨大未開發需求。此外，世界老齡化人口的增加預計將增加未來的市場需求。

生物技術和製藥行業在研發上的巨額支出以及強大的管道可用性預計將成為未來一段時間推動肝病治療市場成長的主要因素。政府和大公司的疫苗接種計劃正在提高人們對這種疾病和預防的認知，從而促進市場成長。

市場分為兩部分：產品和區域。新產品不斷推出，推動市場成長。主要企業之間的策略聯盟和合資企業以及未來國家不斷提高的醫療保健意識推動了市場成長。

肝病藥物市場報告亮點

  • 在全球肝病治療藥物市場中，抗病毒藥物領域佔據主導地位，2023年銷售量為30.3%。肝炎的高盛行率導致肝病患者數的增加。
  • 在全球肝病和老年人口盛行率上升的推動下，預計標標靶治療領域在預測期內的複合年成長率將達到 7.2%。
  • 肝炎細分市場在全球肝病治療藥物市場中佔據主導地位，到 2023 年收益佔有率將達到 36.6%。
  • 非酒精性脂肪肝病 (NAFLD) 預計將在預測期內成長最快，複合年成長率為 6.6%。此細分市場的成長是由肥胖流行率的增加以及隨之而來的肝細胞中脂肪的累積所驅動的。
  • 北美肝病治療藥物市場在全球肝病治療藥物市場中佔據主導地位，2023年收益佔有率為38.4%。
  • 預計亞太地區肝病治療市場在預測期內將以 7.4% 的複合年成長率成長最快。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章 肝病治療藥物市場的變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 肝病治療藥物市場分析工具
    • 波特的分析
    • PESTEL分析

第4章肝病治療藥物市場：依藥物類別估計與趨勢分析

  • 細分儀表板
  • 肝病藥物市場：2023年及2030年依藥物類別變化分析
  • 抗病毒藥物
  • 疫苗
  • 化療
  • 標靶治療
  • 免疫抑制劑
  • 免疫球蛋白
  • 皮質類固醇
  • 其他產品

第5章肝病治療藥物市場：依疾病分類的估算與趨勢分析

  • 細分儀表板
  • 肝病治療藥物市場：2023年及2030年疾病特異性變異分析
  • 肝炎
  • 自體免疫疾病
  • 非酒精性脂肪肝（NAFLD）
  • 癌症
  • 遺傳疾病
  • 其他疾病

第6章 肝病治療藥物市場：區域估計與趨勢分析

  • 2023年及2030年肝病藥物市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • Takeda Pharmaceutical Company Limited
    • Gilead Sciences, Inc.
    • Johnson &Johnson Services, Inc.
    • Merck &Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • AbbVie Inc.
    • Bristol-Myers Squibb Company
    • GlaxoSmithKline PLC
簡介目錄
Product Code: 978-1-68038-540-3

Liver Disease Therapeutics Market Growth & Trends:

The global liver disease therapeutics market is expected to be valued at USD 28.62 billion by 2030, registering a CAGR of 5.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The major driving factors are increasing numbers of liver diseases like hepatocellular carcinoma and vast unexploited need of patients with these types of diseases. In addition, increasing geriatric population globally is estimated to augment the market demand in the future period.

Huge expenditure by biotechnology and pharmaceutical industries on R&D and availability of sturdy pipeline are the major expected boosting factors for the growth of liver diseases therapeutics market in future period. Governments' and big companies' vaccination program are creating awareness about the illness and prevention is boosting the growth of the market.

The market is bifurcated into products and regions. New products are rapidly being launched boosting the market growth. The growth of the market is boosted by the strategic alliances, joint venture between the major players, and growing awareness of healthcare in the upcoming nations.

Liver Disease Therapeutics Market Report Highlights:

  • The antiviral drugs segment dominated the market in the global liver disease therapeutics market with a revenue share of 30.3% in 2023. The high incidence of hepatitis diseases contributes to the rise in liver disease cases.
  • The targeted therapy segment is expected to register the fastest CAGR of 7.2% over the forecast period, driven by the rising incidence of liver diseases and geriatric population globally.
  • The hepatitis segment dominated the global liver disease therapeutics market with a revenue share of 36.6% in 2023.
  • Non-alcoholic fatty liver disease (NAFLD) is expected to register the fastest growth over the forecast period with a CAGR of 6.6%. Segment growth is fueled by the increasing prevalence of obesity and associated fat accumulation in liver cells.
  • North America liver disease therapeutics market dominated the global liver disease therapeutics market with a revenue share of 38.4% in 2023.
  • Asia Pacific liver disease therapeutics market is expected to have the fastest growth in the forecast period with a CAGR of 7.4%.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Liver Diseases Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
    • 3.3.3. Liver Diseases Therapeutics Market Analysis Tools
    • 3.3.4. Porter's Analysis
      • 3.3.4.1. Bargaining power of the suppliers
      • 3.3.4.2. Bargaining power of the buyers
      • 3.3.4.3. Threats of substitution
      • 3.3.4.4. Threats from new entrants
      • 3.3.4.5. Competitive rivalry
    • 3.3.5. PESTEL Analysis
      • 3.3.5.1. Political landscape
      • 3.3.5.2. Economic and Social landscape
      • 3.3.5.3. Technological landscape
      • 3.3.5.4. Environmental landscape
      • 3.3.5.5. Legal landscape

Chapter 4. Liver Disease Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Liver Disease Therapeutics Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Antiviral Drugs
    • 4.3.1. Antiviral Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Vaccines
    • 4.4.1. Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Chemotherapy
    • 4.5.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Targeted Therapy
    • 4.6.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Immunosuppressants
    • 4.7.1. Immunosuppressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Immunoglobulins
    • 4.8.1. Immunoglobulins Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Corticosteroids
    • 4.9.1. Corticosteroids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Other Products
    • 4.10.1. Other Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Liver Disease Therapeutics Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Liver Disease Therapeutics Market: Disease Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Hepatitis
    • 5.3.1. Hepatitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Autoimmune Diseases
    • 5.4.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Non-alcoholic Fatty Liver Disease (NAFLD)
    • 5.5.1. Non-alcoholic Fatty Liver Disease (NAFLD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Cancer
    • 5.6.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Genetic Disorders
    • 5.7.1. Genetic Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Other Diseases
    • 5.8.1. Other Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Liver Disease Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Liver Disease Therapeutics Market Share, By Region, 2023 & 2030 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. UK Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Norway Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. China
      • 6.4.2.1. China Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Japan Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Australia Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. UAE Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. F. Hoffmann-La Roche Ltd
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/Strategic Initiatives
    • 7.4.2. Takeda Pharmaceutical Company Limited
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/Strategic Initiatives
    • 7.4.3. Gilead Sciences, Inc.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/Strategic Initiatives
    • 7.4.4. Johnson & Johnson Services, Inc.
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/Strategic Initiatives
    • 7.4.5. Merck & Co., Inc.
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/Strategic Initiatives
    • 7.4.6. Novartis AG
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/Strategic Initiatives
    • 7.4.7. Pfizer Inc.
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/Strategic Initiatives
    • 7.4.8. Sanofi
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/Strategic Initiatives
    • 7.4.9. AbbVie Inc.
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/Strategic Initiatives
    • 7.4.10. Bristol-Myers Squibb Company
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/Strategic Initiatives
    • 7.4.11. GlaxoSmithKline PLC
      • 7.4.11.1. Participant's Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Recent Developments/Strategic Initiatives